John Hastewell


John Hastewell served in a series of wide-ranging roles in his nearly 30 years at Novartis. Most recently, he was the Head of Novartis Institutes for Biomedical Research (NIBR) Biologics Center where he was responsible for the discovery of antibody, protein, and nucleic acid-based therapeutics. Formerly, he was the Global Head of the Program Office where he worked on NIBR’s research strategy and portfolio management and oversaw the company’s strategic focus on building their biologics drug pipeline. Before working at NIBR, Dr. Hastewell also served in several leadership roles at Novartis based in the UK, including Head of Thrombosis Research, leadership of biochemistry and pharmacology, as well as overseeing all respiratory research disease projects to ensure rapid and effective translation to the clinic. He was also the Head of a strategy team defining the company’s long-term research direction and led the Immunology Platform across all Novartis disease areas.

Seth Harrison


Seth Harrison is the Founder and Managing Partner of Apple Tree Partners (ATP). He has invested in life sciences since 1991. He is currently the Chairman of ATP companies Braeburn Pharmaceuticals, Stoke Therapeutics, and Limelight Bio. His prior investments include: Syntimmune, Aileron Therapeutics, ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, HeartWare International, Informed Access, SGX Pharmaceuticals, Tokai Pharmaceuticals, Ultracision, and ViroPharma. From 2002 to 2010, he also served on the board of the International Partnership for Microbicides. Prior to founding ATP in 1999, Seth was a general partner at Oak Investment Partners, and before that a venture partner at Sevin Rosen Funds.